Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News

January 21, 2023 · Benzinga

Drug discovery company Mindset Pharma 

MSSTF has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.” 

The application includes the company’s psilocybin analogs lead drug candidate MSP-1014, its backup MSP-1009 and additional pro-drug candidates belonging to the family 1 tryptamine drug compounds.

Both MSP-1014 and MSP-1009 demonstrated improved efficacy and safety profiles with reduced potential side effects and evidence of increased target engagement in preclinical studies. 

“Our early and consistent focus on novelty has created a valuable intellectual property (IP) portfolio. This focus on IP has already created value for Mindset, and today’s announcement is a good indication of the potential for additional returns for Mindset thanks to our ongoing focus on novel optimized psychedelic-inspired medications,” concluded CEO James Lanthier.

PharmaTher Holdings 

PHRRF has applied with the FDA to receive Orphan Drug Designation (ODD) on ketamine therapy for Rett Syndrome. 

This ODD would qualify ketamine for certain benefits and incentives, including seven years of marketing exclusivity for the targeted indication, potential tax credits for certain clinical drug costs, eligibility for orphan drug grants, and the waiver of the FDA New Drug Application filing fee (approx. $2.4 million.)

A recent Phase 2 trial assessed ketamine treatment for this rare genetic neurological disorder. Now, the company will evaluate the study’s unpublished results in support of a potential Phase 3 trial and an FDA-agreed regulatory plan.

PharmaTher currently holds four orphan drug designations granted by the FDA for proprietary racemic ketamine KETARX, including ischemia-reperfusion injury from organ transplantation and Status Epilepticus.

Biopharma home-based solutions company Bexson Biomedical Inc. announced that the USPTO issued patent “Complexing Agent Salt Formulations of Pharmaceutical Compounds” corresponding to its proprietary formulation technology SEVALENT.

The novel technology is the basis for Bexson’s lead therapy BB106 on ketamine for postoperative pain management, a leading driver of opioid addiction.  

Now, the new patent expands its potential utility to additional small molecules, enabling intravenous-only therapies to be delivered subcutaneously in a controlled manner for at-home use. (Full Story)

In categories:Medical Psychedelics
Next Post

The Cannabis vs. Viagra Debate - Which is Better for Sexual Health?

Viagra is the brand name of sildenafil, a class of drugs that are designed for the treatment of erectile dysfunction (ED). Men who suffer from ED struggle with starting and maintaining their erections. Depending on the case, it may be a short-term…
Previous Post

The rebirth of psychedelic medicine

It was 1985 and John Lawn had seen enough.  In Boston nightclubs and Dallas bars, MDMA — better known by its street name, ecstasy — had become an enormously popular recreational drug. It had also terrified the Reagan administration, which…
Random Post

Oregon Audit Forces State Official to Resign Cannabis Consultancy

Other state lawmakers had criticized the business arrangement. Oregon’s secretary of state on Monday cut ties with a marijuana business she’d been consulting with after the business arrangement came to light following a state audit of Oregon’s cannabis industry. “I exercised poor…
Random Post

New Hampshire Lawmakers Refine Marijuana Legalization Plan, With Vote Expected Soon

New Hampshire lawmakers working on marijuana legalization legislation met on Tuesday to refine their plan to advance the reform this session, with members of a committee hashing out differences between competing proposals. The intent is to nail down a merged…
Random Post

New Cannabis Laws Take Effect in 11 US States

Changes are afoot among the rules and regulations governing cannabis in several states this year. Weed laws are evolving in 11 states thanks to voter-drive ballot initiatives, new laws introduced in state legislatures, and executive orders enacted by state governors.…
Random Post

Activists, Advocates, and Opportunists at the Gate

The tone in the North American cannabis industry over the past several months has been one of harsh realities and unprecedented struggles for everyone from small local growers to large multistate operators. Meanwhile, hope for federal legalization seems to lessen…